Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.38 |
| ▸ | CA12 | O43570 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.30 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7814071 | 1.00 | SMN1; SMN2 (0.44) | SMN1; SMN2CA14CA12CA1CA2 | |
| SCHEMBL27522067 | 0.81 | SMN1; SMN2 (0.40) | SMN1; SMN2CA14CA12CA1CA2 | |
| SCHEMBL27521634 | 0.81 | SMN1; SMN2 (0.40) | SMN1; SMN2CA14CA12CA1CA2 | |
| SCHEMBL27521633 | 0.81 | SMN1; SMN2 (0.40) | SMN1; SMN2CA14CA12CA1CA2 | |
| SCHEMBL8186261 | 0.79 | SMN1; SMN2 (0.39) | SMN1; SMN2CA14CA12CA1CA2 | |
| SCHEMBL9459932 | 0.79 | CA1 (0.39) | SMN1; SMN2CA14CA12CA1CA2 | |
| SCHEMBL3993908 | 0.76 | CA1 (0.39) | CA14CA12CA1CA2KMT2A | |
| SCHEMBL2828705 | 0.76 | SMN1; SMN2 (0.40) | SMN1; SMN2CA14CA12CA1CA2 | |
| SCHEMBL6669359 | 0.75 | PTGS1 (0.48) | SMN1; SMN2CA1CA2 | |
| SCHEMBL6669356 | 0.75 | PTGS1 (0.48) | SMN1; SMN2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114450283-B | 3, 6-Diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their use as pro-apoptotic agents | 法国施维雅药厂 | 2024-05-07 | — | — | CN | disclosed |
| CN-110997605-B | Synthesis of diols by transfer hydrogenation of alpha-functionalized esters with alcohols | 伊士曼化工公司 | 2023-07-25 | — | — | CN | disclosed |
| CN-114450283-A | 3, 6-diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their use as pro-apoptotic agents | 法国施维雅药厂 | 2022-05-06 | — | — | CN | disclosed |
| EP-3661901-A1 | SYNTHESIS OF GLYCOLS VIA TRANSFER HYDROGENATION OF ALPHA-FUNCTIONAL ESTERS WITH ALCOHOLS | Eastman Chemical Company (US) | 2020-06-10 | — | — | EP | disclosed |
| WO-2019027948-A1 | SYNTHESIS OF GLYCOLS VIA TRANSFER HYDROGENATION OF ALPHA-FUNCTIONAL ESTERS WITH ALCOHOLS | EASTMAN CHEMICAL COMPANY (US) | 2019-02-07 | — | — | WO | disclosed |
| US-9062051-B2 | Compounds and pharmaceutical compositions thereof for the treatment of proliferative disorders | GALAPAGOS NV (BE) | 2015-06-23 | — | — | US | disclosed |
| US-20150080391-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | GALAPAGOS NV (BE) | 2015-03-19 | — | — | US | disclosed |
| EP-0347811-B1 | Alkanoic acid derivatives and herbicidal compositions | KUMIAI CHEMICAL INDUSTRY CO (JP) | 1994-03-30 | — | — | EP | disclosed |
| US-5087289-A | ALKANOIC ACID DERIVATIVES AND HERBICIDAL COMPOSITIONS | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 1992-02-11 | — | — | US | disclosed |
| US-4968340-A | PREEMERGENCE | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 1990-11-06 | — | — | US | disclosed |
| EP-0347811-A1 | Alkanoic acid derivatives and herbicidal compositions | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 1989-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080391-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | FGF2, CCNA2, VEGFA | SMN1; SMN2 580/4885CA14 823/4885CA12 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.